149 related articles for article (PubMed ID: 27181230)
21. T cell memory, anergy and immunotherapy in breast cancer.
Schirrmacher V; Feuerer M; Beckhove P; Ahlert T; Umansky V
J Mammary Gland Biol Neoplasia; 2002 Apr; 7(2):201-8. PubMed ID: 12463740
[TBL] [Abstract][Full Text] [Related]
22. Harnessing the Microbiome to Enhance Cancer Immunotherapy.
Nelson MH; Diven MA; Huff LW; Paulos CM
J Immunol Res; 2015; 2015():368736. PubMed ID: 26101781
[TBL] [Abstract][Full Text] [Related]
23. Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen presentation during clearance of a persistent viral infection.
Lauterbach H; Zuniga EI; Truong P; Oldstone MB; McGavern DB
J Exp Med; 2006 Aug; 203(8):1963-75. PubMed ID: 16847068
[TBL] [Abstract][Full Text] [Related]
24. T-memory cells against cancer: Remembering the enemy.
Sarkar I; Pati S; Dutta A; Basak U; Sa G
Cell Immunol; 2019 Apr; 338():27-31. PubMed ID: 30928016
[TBL] [Abstract][Full Text] [Related]
25. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory.
Dai J; Liu B; Caudill MM; Zheng H; Qiao Y; Podack ER; Li Z
Cancer Immun; 2003 Jan; 3():1. PubMed ID: 12747743
[TBL] [Abstract][Full Text] [Related]
26. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA
Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877
[TBL] [Abstract][Full Text] [Related]
27. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model.
Bourquin C; von der Borch P; Zoglmeier C; Anz D; Sandholzer N; Suhartha N; Wurzenberger C; Denzel A; Kammerer R; Zimmermann W; Endres S
J Immunol; 2010 Aug; 185(4):2580-8. PubMed ID: 20644173
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel human memory T-cell population with the characteristics of stem-like chemo-resistance.
Murata K; Tsukahara T; Emori M; Shibayama Y; Mizushima E; Matsumiya H; Yamashita K; Kaya M; Hirohashi Y; Kanaseki T; Kubo T; Himi T; Ichimiya S; Yamashita T; Sato N; Torigoe T
Oncoimmunology; 2016 Jun; 5(6):e1165376. PubMed ID: 27471640
[TBL] [Abstract][Full Text] [Related]
29. Vitamin C treatment of mouse bone marrow-derived dendritic cells enhanced CD8(+) memory T cell production capacity of these cells in vivo.
Jeong YJ; Kim JH; Hong JM; Kang JS; Kim HR; Lee WJ; Hwang YI
Immunobiology; 2014 Jul; 219(7):554-64. PubMed ID: 24698552
[TBL] [Abstract][Full Text] [Related]
30. Rewiring Mitochondrial Metabolism for CD8
Li W; Zhang L
Front Immunol; 2020; 11():1834. PubMed ID: 32983095
[TBL] [Abstract][Full Text] [Related]
31. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
32. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
33. [Development of next-generation peptide vaccination therapy].
Tsukahara T; Hirohashi Y; Emori M; Torigoe T
Nihon Rinsho; 2017 Feb; 75(2):270-274. PubMed ID: 30562863
[TBL] [Abstract][Full Text] [Related]
34. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory.
Schirrmacher V
Cancer Immunol Immunother; 2005 Jun; 54(6):587-98. PubMed ID: 15838708
[TBL] [Abstract][Full Text] [Related]
35. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
36. Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.
Chapatte L; Colombetti S; Cerottini JC; Lévy F
Cancer Res; 2006 Jan; 66(2):1155-60. PubMed ID: 16424053
[TBL] [Abstract][Full Text] [Related]
37. Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation.
Veliça P; Zech M; Henson S; Holler A; Manzo T; Pike R; Santos E Sousa P; Zhang L; Heinz N; Schiedlmeier B; Pule M; Stauss H; Chakraverty R
Cancer Res; 2015 Jul; 75(13):2641-52. PubMed ID: 25904681
[TBL] [Abstract][Full Text] [Related]
38. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
39. The future of immunotherapy for sarcoma.
Tsukahara T; Emori M; Murata K; Mizushima E; Shibayama Y; Kubo T; Kanaseki T; Hirohashi Y; Yamashita T; Sato N; Torigoe T
Expert Opin Biol Ther; 2016 Aug; 16(8):1049-57. PubMed ID: 27158940
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
